OVARIAN CANCER

Ovarian cancer is the worst prognosis of gynecologic tumors. Patients with advanced epithelial ovarian cancer five-year survival rates generally below 30%, mainly in patients with relapsing most (about 75%), relapse after chemotherapy to poor results.

For the treatment of recurrent ovarian cancer chemotherapy drugs many, no less than 10 species, but only clinical remission rate of 20% to 30%, no progress median survival time (PFS) for 2 to 6 months, the median overall survival (OS) for six to 12 months. Therefore, to improve the efficacy of chemotherapy drugs delay, but the development of new drugs is very difficult, efficient use of existing drugs is an effective way to <BR>.

Tags: cancer, cases, chemotherapy, cisplatin, clinical, drug, drugs, early, eat, exploration, gene, group, method, ovarian, p53, paclitaxel, patients, pmtc, poor, positive, prognosis, rate, second, study, survival, taxol, therapy, time, treatment, tumor, tumors

Cytoreductive surgery in the treatment of ovarian cancer Comprehensive Application and prospects

Foreign Medical Obstetrics and Gynecology volumes in 1999 Vol 26 No. 2

Tianjin Medical University General Hospital of Obstetrics and Gynecology (300,052) of the new QU (Summary) if Mi (revision)

Abstract <BR> since the 1980s, complete cytoreductive surgery to cisplatin-based combination chemotherapy for ovarian cancer as a conventional model, cytoreductive surgery is the complete impact of the prognosis of patients with one of the important factors for recurrent ovarian cancer once again cytoreductive surgery still some value , but to improve the survival rate of patients is more important to be effective after chemotherapy treatment as a necessary complement. Early ovarian cancer retroperitoneal lymph node dissection is reasonable and significance of the still controversial.

Tags: abdominal, age, annex, anti, bleeding, blood, cancer, cases, cause, cell, cells, chemotherapy, cisplatin, clinical, diagnosis, drug, drugs, early, eat, ert, exploration, gene, growth, incidence, increased, intraperitoneal, intravenous, life, lymph, malignant, metastasis, metastatic, method, mutation, node, ovarian, p53, patients, pelvic, physical, poor, positive, prognosis, quality, rate, reduce, resection, residual, response, second, staging, study, surgery, surgical, survival, therapy, time, toxicity, treatment, tumor, tumors

Abstract: a group P53 mutations in the genes in patients with advanced ovarian cancer by more cycles of P53 gene therapy and chemotherapy, reducing disease, the survival rate has improved. (The Fourth Annual Gene Therapy & Molecular Biology Conference, Rhodes, Greece)

American University of Iowa Dr. Richard Buller reported they received early treatment to strengthen the 36 patients with advanced ovarian cancer to the adenovirus vector into the peritoneal tumor suppressor gene p53 function of the combination of chemotherapy I / II clinical trials of the preliminary results. The results show that several gene therapy / chemotherapy combination therapy in patients with an average survival of 14.8. Nine people have survived 19.5 months, are still alive. The survival rate is higher than five separate gene therapy on the survival rate is also higher than the average with paclitaxel (Taxol) in the treatment of recurrent ovarian cancer new 15-month survival rate.

Tags: age, cancer, carboplatin, cause, chemotherapy, clinical, early, eat, gene, group, intraperitoneal, mutation, ovarian, p53, paclitaxel, patients, rate, reduce, survival, taxol, therapy, treatment, tumor

Kikuchi, the Japanese report, have received platinum multidrug chemotherapy for recurrent ovarian cancer Japanese women, a weekly carboplatin and paclitaxel chemotherapy in a meeting, can significantly prolong survival, and patients can be tolerated. (Int J Cancer YORK 2005,15:45)

The case control study included surgery and platinum-based adjuvant chemotherapy complete remission for at least 6 months after the recurrence of ovarian cancer patients. Of the 68 patients, 27 patients received a weekly meeting of Taxol and carboplatin chemotherapy (WTJ) (Group I), carboplatin (AUC area under the curve for 2) plus paclitaxel (80 mg/m2); The remaining 41 patients (Group II) to platinum-based (P ) other chemotherapy, 37 patients with CAP program, a monthly meeting of carboplatin and paclitaxel program four cases.

Tags: cancer, carboplatin, cases, chemotherapy, clinical, drug, drugs, eat, family, gene, group, growth, increased, intraperitoneal, method, ovarian, ovary, p53, paclitaxel, patients, preventive, prognosis, protein, rate, risk, screening, second, study, surgery, survival, syndrome, taxol, therapy, time, treatment, women

Usually that cervical cancer is a certain type of human papilloma virus (HPV) caused. Now Johns Hopkins University researchers think that some head and neck cancer, particularly tongue and tonsil cancer with the following regional HPV infection. They also found that HPV-positive head and neck cancer prognosis, the other with head and neck cancer different.

V. said Dr. Keerti Shah, head and neck cancer usually is not a good prognosis, in the majority of patients the disease is advanced only found. However, HPV-positive cancer under the microscope is obvious characteristics, so pathologists can immediately determine whether the HPV-positive tumors.

Tags: cancer, cases, cause, diagnosis, eat, ert, gene, head, hpv, mutation, neck, p53, patients, positive, prognosis, radiation, risk, study, treatment, tumor, tumors, usually

For a long time, ovarian cancer is malignant gynecologic tumors in the highest degree. In the United States, the mortality rate since 1979 as medical research has not progressed any lower, always maintained at about 9.8 per 100,000.

Currently known ovarian cancer in a related gene p53 gene. The human gene that regulates the transcription of certain genes, thereby inhibiting cell proliferation and repair damage cells. The function of this gene defect could lead to abnormal cell proliferation occurring.

Tags: age, anti, body, cancer, cause, cell, cells, chemotherapy, drug, drugs, early, eat, ert, gene, life, malignant, metastasis, method, mutation, ovarian, p53, patients, poor, positive, prognosis, protein, rate, reduce, risk, study, survival, therapy, time, tumor, tumors

Henan Medical University, a professor of obstetrics and gynecology buildings Qiao Yu, graduate students and others Rui - Xia Guo recent study found that in some tumor suppressor gene amplification or overexpression of ovarian cancer is the key factor. Entitled "epithelial ovarian cancer tumor mechanism and clinical application of" scientific research, recently Henan "progress of science and technology second prize."

Tags: anti, benign, cancer, carcinoma, cases, cell, clinical, cyst, early, eat, ert, gene, incidence, increased, life, malignant, maspin, metastasis, metastatic, mutation, ovarian, p53, patients, positive, rate, second, study, survival, tumor, tumors